Answers are grounded in this paper and cite their sources.
Evaluates carfilzomib mechanisms and cardiac complications in refractory multiple myeloma, highlighting the balance between therapeutic efficacy and cardiovascular safety.
Carfilzomib is a novel, highly selective, tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, which is the proteolytic core particle within the 26S proteasome, as compared with bortezomib, which reversibly inhibits the 20S proteasome. 1 In vitro , carfilzomib has demonstrated antiproliferative and proapoptotic activities in solid and hematologic tumor cells. 2
No takes yet. Share an insight, caveat, or question.
Atrash et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: